BR112017018029A2 - molécula de sirna, utilização de um sirna, método para a redução da transpiração e composição antitranspirante - Google Patents

molécula de sirna, utilização de um sirna, método para a redução da transpiração e composição antitranspirante

Info

Publication number
BR112017018029A2
BR112017018029A2 BR112017018029A BR112017018029A BR112017018029A2 BR 112017018029 A2 BR112017018029 A2 BR 112017018029A2 BR 112017018029 A BR112017018029 A BR 112017018029A BR 112017018029 A BR112017018029 A BR 112017018029A BR 112017018029 A2 BR112017018029 A2 BR 112017018029A2
Authority
BR
Brazil
Prior art keywords
sirna
antiperspirant composition
reducing perspiration
reducing
molecule
Prior art date
Application number
BR112017018029A
Other languages
English (en)
Other versions
BR112017018029B1 (pt
Inventor
Bovell Douglas
Robertson Jennifer
Livesey Evans Richard
Original Assignee
Unilever Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Nv filed Critical Unilever Nv
Publication of BR112017018029A2 publication Critical patent/BR112017018029A2/pt
Publication of BR112017018029B1 publication Critical patent/BR112017018029B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção se refere a um método para a redução da transpiração que compreende a aplicação tópica de uma composição que compreende um sirna que é capaz de reduzir os níveis de uma proteína especificada ou o seu mrna ou a função ou formação de canal de cálcio associado a ele; em que a proteína especificada é a orai1, stim1, orai3, trpc1 ou stim2.
BR112017018029-4A 2015-03-20 2016-03-10 Molécula de sirna, método para a redução da perspiração, composição antiperspirante e uso de uma composição antiperspirante BR112017018029B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15160174 2015-03-20
EP15160174.7 2015-03-20
PCT/EP2016/055157 WO2016150723A1 (en) 2015-03-20 2016-03-10 Antiperspirant composition

Publications (2)

Publication Number Publication Date
BR112017018029A2 true BR112017018029A2 (pt) 2018-04-10
BR112017018029B1 BR112017018029B1 (pt) 2021-06-15

Family

ID=52686284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018029-4A BR112017018029B1 (pt) 2015-03-20 2016-03-10 Molécula de sirna, método para a redução da perspiração, composição antiperspirante e uso de uma composição antiperspirante

Country Status (6)

Country Link
US (1) US10227594B2 (pt)
EP (1) EP3270881B1 (pt)
AU (1) AU2016236521B2 (pt)
BR (1) BR112017018029B1 (pt)
MX (1) MX367563B (pt)
WO (1) WO2016150723A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3084824A1 (en) 2017-12-15 2019-06-20 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
CA3128644A1 (en) * 2019-03-01 2020-09-10 Avak Kahvejian Polyribonucleotides and cosmetic uses thereof
EP4351739A2 (en) 2021-06-07 2024-04-17 Unilever IP Holdings B.V. Compositions and methods for controlling sweat production

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797447B1 (fr) 1999-08-12 2004-04-02 Univ Clermont Auvergne "odorant-binding" proteines humaines fixant des ligands hydrophobes:polypeptides et polynucleotides codant lesdits polypeptides et leurs applications
FR2804960B1 (fr) 2000-02-11 2005-06-24 Lvmh Rech Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
GB0019055D0 (en) 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
FR2840217B1 (fr) 2002-06-03 2005-06-24 Oreal Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
PT2284266E (pt) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US7504385B2 (en) 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
DE102004010547A1 (de) 2004-03-03 2005-11-17 Beiersdorf Ag Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
EP1814996A2 (en) 2004-11-19 2007-08-08 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
DE102005001784A1 (de) 2005-01-13 2006-10-05 Beiersdorf Ag Oligoribonukleotide zur Reduktion der Schweißbildung durch RNA-Interferenz
US7534762B2 (en) 2005-03-18 2009-05-19 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007046102A2 (en) 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
WO2007068735A1 (en) 2005-12-14 2007-06-21 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding same
PT2170403E (pt) 2007-06-27 2014-07-17 Quark Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes pró-apoptóticos
US8618160B2 (en) 2007-10-18 2013-12-31 Rose U Topical glycopyrrolate formulations
EP2201113B1 (en) 2007-10-18 2015-09-16 SNU R & DB Foundation Method of identifying agents which modulate the activity of calcium-activated chloride channel
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
FR2948021A1 (fr) 2009-07-16 2011-01-21 Oreal Utilisation cosmetique de polypeptides de type lacritine
EP2814455B1 (en) 2012-02-13 2017-07-19 Unilever N.V. A skin lightening composition
WO2014027050A1 (en) 2012-08-16 2014-02-20 Brain Biotechnology Research And Information Network Ag A novel calcium-activated chloride channel involved in human sweat formation
JP6242402B2 (ja) 2013-01-03 2017-12-06 ハイドロス セラピューティクス インターナショナル アクチエボラグ 多汗症の治療
EP2865758A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene

Also Published As

Publication number Publication date
MX367563B (es) 2019-08-27
US10227594B2 (en) 2019-03-12
EP3270881A1 (en) 2018-01-24
EP3270881B1 (en) 2018-12-26
WO2016150723A1 (en) 2016-09-29
AU2016236521A1 (en) 2017-09-07
AU2016236521B2 (en) 2019-03-07
MX2017012019A (es) 2018-01-30
BR112017018029B1 (pt) 2021-06-15
US20180037894A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
BR112017018316A2 (pt) composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112019001902A2 (pt) composição para profilaxia ou tratamento de doenças relacionadas à il-8
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
BR112018007017A2 (pt) polipeptídeos
DOP2022000082A (es) Heterociclos bicíclicos como inhibidores de fgfr
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112017019054A2 (pt) métodos para o tratamento de pele
BR112017012377A2 (pt) conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112016028255A2 (pt) agentes imunorreguladores
BR112017023374A2 (pt) formulação de anticorpo anti-cgrp
BR112018005194A2 (pt) processo de composto antifúngico
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112019006987A2 (pt) inibidores de receptor de glicocorticoide
BR112017002369A2 (pt) derivados de diazepana e usos dos mesmos
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
EA201592113A1 (ru) Двойные селективные ингибиторы pi3-киназ дельта и гамма
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
BR112017022281A2 (pt) métodos para tratar câncer
BR112014032764A2 (pt) composição farmacêutica contendo fimasartana e hidroclorotiazida

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNILEVER IP HOLDINGS B.V. (PB)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2016, OBSERVADAS AS CONDICOES LEGAIS.